Treatment also attenuated Tau hyperphosphorylation at different epitopes in 3xTg and 5XFAD mice [103,104] and reduced the level of p38 mitogen-activated protein kinase (MAPK), which is a kinase that is overactivated in patients with AD [107]. This evidence concerns the gene MAPT and Alzheimer disease.